Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | 1.32% | 697.33 | 2.6% | $644.85m | |
| MRNA | Moderna, Inc. | -0.55% | 123.64 | 0.0% | $634.51m | |
| AMGN | Amgen, Inc. | -0.34% | 226.97 | 1.4% | $624.69m | |
| GILD | Gilead Sciences, Inc. | -1.43% | 62.86 | 1.0% | $494.49m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.01% | 283.45 | 1.9% | $355.83m | |
| ILMN | Illumina, Inc. | -1.61% | 190.38 | 3.2% | $291.37m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -5.81% | 4.05 | 0.7% | $283.11m | |
| BIIB | Biogen, Inc. | -1.42% | 197.78 | 1.8% | $184.42m | |
| SAVA | Cassava Sciences, Inc. | -18.00% | 41.87 | 0.0% | $173.71m | |
| BNTX | BioNTech SE | -1.27% | 128.35 | 0.0% | $100.39m | |
| NRBO | NeuroBo Pharmaceuticals, Inc. | -6.44% | 15.54 | 0.0% | $89.03m | |
| NVAX | Novavax, Inc. | -6.42% | 21.00 | 75.6% | $85.66m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -0.09% | 84.84 | 4.2% | $76.07m | |
| EXAS | EXACT Sciences Corp. | -2.74% | 33.41 | 17.6% | $71.49m | |
| CRSP | CRISPR Therapeutics AG | -2.68% | 63.16 | 0.6% | $69.53m |
Company Profile
Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), and related conditions and diseases along with its development of prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease and cancer. As of December 31, 2009, it was focused on its drug development resources on two clinical stage development projects: droxidopa for symptomatic NOH and other potential indications, and its portfolio of non-metabolized antifolate compounds for the treatment of rheumatoid arthritis.